Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Majid Vakily"'
Publikováno v:
Current Medical Research and Opinion. 25:627-638
Dexlansoprazole MR is a novel Dual Delayed Release formulation of dexlansoprazole, an enantiomer of lansoprazole, designed to prolong the plasma concentration-time profile of dexlansoprazole and extend duration of acid suppression with once-daily (QD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e434ba73c06e2de4f6fb0dc17497d97
https://doi.org/10.1185/03007990802693883
https://doi.org/10.1185/03007990802693883
Publikováno v:
The Journal of Clinical Pharmacology. 45:1179-1186
Drugs prescribed for rheumatoid arthritis are often associated with gastrointestinal toxicity, and proton pump inhibitors may be coadministered for gastroprotection. In this open-label study, the effect of lansoprazole 30 mg qd and naproxen 500 mg bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::849021a3d7890fd6fb9ccc8cd7a8c634
https://doi.org/10.1177/0091270005280100
https://doi.org/10.1177/0091270005280100
Publikováno v:
Pharmaceutical Research. 16:123-129
Purpose. To test the hypothesis that modification of release pattern of nonsteroidal anti-inflammatory drugs (NSAIDs) formulations shifts gastrointestinal (GI) toxicity of the drugs from the upper GI region to the distal intestine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::118daf60e8204139c3e225fcfe262ad9
https://doi.org/10.1023/a:1018887216098
https://doi.org/10.1023/a:1018887216098
Autor:
Majid Vakily, Fakhreddin Jamali
Publikováno v:
Journal of Pharmaceutical Sciences. 85:638-642
A new direct stereospecific HPLC method was developed to assay tiaprofenic acid (TA) enantiomers in plasma. It has been reported previously that TA exhibits nonstereoselective pharmacokinetics in humans using an indirect stereospecific HPLC assay. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e973bf9f7b41e58ed54e300668968bbd
https://doi.org/10.1021/js950312d
https://doi.org/10.1021/js950312d
Publikováno v:
Journal of Pharmaceutical Sciences. 84:1014-1019
β -Cyclodextrin was ethylated at the 2- and 6-hydroxyl positions. Diethyl sulfate was employed as an alkylating reagent. NMR spectra data indicate that heptakis(2,6-di- O -ethyl)- β -cyclodextrin (DCD) is the principal component of the product obta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bec15583fed851284e59f49d745eba4
https://doi.org/10.1002/jps.2600840819
https://doi.org/10.1002/jps.2600840819
Publikováno v:
Pharmaceutical Research. 12:1652-1657
Purpose. A comparison of a previously reported indirect (precolumn derivatization) assay for ketorolac (KT) and a new direct method described here was made to establish the conditions under which KT may undergo racemization and to explain the observe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::127ac1e2dfbb45a113d3bdda1efd31d8
https://doi.org/10.1023/a:1016245101389
https://doi.org/10.1023/a:1016245101389
Publikováno v:
Journal of clinical pharmacology. 49(12)
The effect of the proton pump inhibitor dexlansoprazole, an enantiomer of lansoprazole, on QT intervals was assessed after oral administration of a modified-release formulation of dexlansoprazole (dexlansoprazole MR). In this randomized, positive-com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1245bd7dd01ce5b68cc35cde5675922
https://pubmed.ncbi.nlm.nih.gov/19826060
https://pubmed.ncbi.nlm.nih.gov/19826060
Publikováno v:
Alimentary pharmacologytherapeutics. 29(9)
Summary Background Proton pump inhibitors (PPIs) provide the most effective pharmacotherapy for treating acid-related disorders. However, PPIs do not completely control acid over 24 h with once-daily dosing. Aims To discuss limitations inherent in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d2facd9170ec531bef42f7a06c712a8
https://pubmed.ncbi.nlm.nih.gov/19298580
https://pubmed.ncbi.nlm.nih.gov/19298580
Publikováno v:
Alimentary pharmacologytherapeutics. 29(8)
Summary Background Dexlansoprazole MR is a proton pump inhibitor with a Dual Delayed Release (DDR) formulation designed to prolong the dexlansoprazole plasma concentration–time profile. The presence of food or time of dosing relative to food may af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8fe4458efca5b7a69d092cde2e609ae
https://pubmed.ncbi.nlm.nih.gov/19243357
https://pubmed.ncbi.nlm.nih.gov/19243357
Publikováno v:
Clinical drug investigation. 29(1)
Background and objective: Most proton pump inhibitors are extensively metabolized by cytochrome P450 (CYP) isoenzymes, as are many other drugs, giving rise to potential drug-drug interactions. Dexlansoprazole modified release (MR) [TAK-390MR] is a mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c51d470cafab16822663861326ad0a95
https://pubmed.ncbi.nlm.nih.gov/19067473
https://pubmed.ncbi.nlm.nih.gov/19067473